Home

PAUL V MAIER

CIK 1182615 · Chief Financial Officer · last filed 2026-08-31

PAUL V MAIER is a Chief Financial Officer who has filed 134 SEC Form 4 insider transactions across 8 companies since 2008. The most recent filing, for ETON, was dated Aug 31, 2026. Across all open-market trades the lifetime net is −$5.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.4M across reported positions. 18 SEC filings were submitted jointly with LIGAND PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.41M

Companies

8

Total Filings

134

Lifetime Open-Market Net

-$5.87M

Filer Profile

Reported Address
4720 DOVEDALE DRIVE
WILLIAMSBURG, VA 23188
Related Filers
LIGAND PHARMACEUTICALS INC — 18 joint filings, latest 2006-11-22
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ETON Director 59,745 $57.08 $3.41M -$5.88M 12 2026-08-31
Ambrx Biopharma, Inc. (AMAM) Delisted Director 85,000 $28.00 $2.38M $0 3 2024-03-07
Qualigen Therapeutics, Inc. (RTTR) Delisted Director — — — $0 5 2020-01-17
MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted Director 23,063 — — -$30.3K 12 2018-04-04
SEELOS THERAPEUTICS, INC. (APRI) Delisted Director 462 — — $0 11 2018-01-08
SEQUENOM INC (SQNM) Delisted Chief Financial Officer 76,927 — — $28.6K 18 2014-02-12
PURE BIOSCIENCE, INC. (PURE) Delisted Director 8,639 — — $0 2 2012-08-02
Talon Therapeutics, Inc. (HNAB) Delisted Director 1,750 — — $5.2K 4 2009-02-26

Recent Filings

134 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-31 ETON Mixed +12,500 -$2.67M EDGAR
2026-08-28 ETON Notice (144) −50,000 -$2.95M EDGAR
2026-08-28 ETON Mixed — -$2.76M EDGAR
2026-08-04 ETON Grant (A) — $0 EDGAR
2026-06-23 — Grant (A) — $0
2026-01-14 ETON Grant (A) — $0 EDGAR
2025-06-20 — Grant (A) — $0
2025-01-06 ETON Grant (A) — $0 EDGAR
2024-06-13 — Grant (A) — $0
2024-03-07 Ambrx Biopharma, Inc. (AMAM) Delisted Disp (D) — $0 EDGAR
Showing 1–10 of 134
Page 1 of 14
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.